Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pacific Biomarkers CSO Elizabeth T. Leary Co-Authors Paper in March Issue of Clinical Chemistry

Published: Wednesday, March 09, 2011
Last Updated: Wednesday, March 09, 2011
Bookmark and Share
Article explores the contribution of assay methodologies in risk classification for cardiovascular disease.

Elizabeth T. Leary, PhD, Chief Scientific Officer at Pacific Biomarkers, Inc. (PBI), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has co-authored a paper appearing in the March issue of Clinical Chemistry. The article explores the contribution of assay methodologies in the risk score classification of cardiovascular disease.

In the paper, Dr. Leary and her co-authors evaluated the accuracy of cardiovascular disease risk score classification by direct LDL cholesterol, calculated LDL cholesterol, and non-HDL cholesterol compared to classification by reference measurement procedures performed at the Centers for Disease Control and Prevention.

A total of 175 individuals were examined, including 138 with cardiovascular disease or conditions that may affect measurement of LDL cholesterol.

The study concluded that except for individuals with elevated triglycerides, 7 of 8 direct LDL cholesterol methods failed to show improved cardiovascular disease risk score classification over the corresponding calculated LDL cholesterol methods.

Non-HDL cholesterol showed overall the best concordance with the reference measurement procedures for cardiovascular disease risk score classification of both normal and hypertriglyceridemic individuals.

"Most clinical papers pretty much ignore assay differences and their contribution in the interpretation of study findings," said Dr. Leary. "We have presented evidence that not all assays for cardiovascular risk are equally accurate, a conclusion that may help select the appropriate assay for each study and refine methodologies that target those patients at risk for cardiovascular disease."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration
PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services.
Tuesday, March 11, 2014
Pacific Biomarkers Announces New Chief Scientific Officer
Pacific Biomarkers names the company's current Vice President, Research and Development, Amar A. Sethi, MD, PhD, as the new Chief Scientific Officer.
Tuesday, January 03, 2012
Pacific Biomarkers' Dr. Amar A. Sethi Honored by Pharmaceutical Executive Magazine as One of 30 Emerging Pharma Leaders of 2011
Vice president of R&D called "A Pathfinder in Drug Development".
Wednesday, June 29, 2011
Pacific Biomarkers' Dr. Amar A. Sethi Recognized by R&D Directions as One of Nine "Most Notable People in R&D"
Vice President of R&D singled out for work in seeking clues to heart-disease risk.
Thursday, March 03, 2011
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!